(Q37766502)

22 August 2017

title

New frontiers of HCV therapy in HIV/HCV co-infection (English)

1 reference

22 August 2017

Valerianna K Amorosa

1

1 reference

22 August 2017

publication date

1 August 2010

1 reference

22 August 2017

published in

Current HIV/AIDS reports

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

117-126

1 reference

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-010-0051-7

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

21 January 2018

1 reference

12 December 2020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

12 December 2020

The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation

1 reference

12 December 2020

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

1 reference

12 December 2020

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

1 reference

12 December 2020

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

12 December 2020

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

1 reference

12 December 2020

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

12 December 2020

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

1 reference

12 December 2020

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

12 December 2020

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

12 December 2020

Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

The HBV drug entecavir - effects on HIV-1 replication and resistance

1 reference

12 December 2020

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

12 December 2020

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century

1 reference

12 December 2020

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors

1 reference

12 December 2020

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

12 December 2020

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

12 December 2020

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo

1 reference

12 December 2020

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

1 reference

12 December 2020

10.1007/S11904-010-0051-7

Identifiers

DOI

1 reference

22 August 2017

1 reference